Peptide · Fact sheet
Semaglutide
Also known as Ozempic · Wegovy · Rybelsus
Semaglutide is the active ingredient in several FDA-approved prescription medicines. Approval is product- and use-specific; it does not make every semaglutide product or every claimed use approved.
What is Semaglutide?
Semaglutide is a manufactured peptide-like medicine that acts on the GLP-1 receptor, part of a signaling system involved in blood sugar, appetite, and digestion.
The active ingredient appears in different prescription products. Those products are not interchangeable in every context, and their FDA labels differ.
Benefits & claims
People commonly search for semaglutide because of its established roles in type 2 diabetes care and chronic weight management.
Researchers also study cardiovascular, kidney, liver, and other outcomes. A study result does not automatically create a new approved use.
What the evidence supports
- Randomized trials show clinically meaningful benefits for the uses and populations described in approved labels.
- Ongoing studies are asking whether benefits extend to additional conditions; those questions should remain separate from established indications.
Research areas
- Type 2 diabetes
- Chronic weight management
- Cardiovascular outcomes
- Kidney outcomes
- Metabolic liver disease
- Additional outcomes beyond the exact product label and population
- Uses outside the population or indication of a particular FDA-approved label
Dosage & frequency
Product-specific label informationSemaglutide regimens differ by brand, route, indication, and age. Weekly injection amounts and daily tablet amounts are not interchangeable.
Wegovy injection
Adults meeting weight-management criteria; patients age twelve and older with obesity
- Amount
- Start 0.25 mg; four-week steps 0.5, 1 and 1.7 mg; maintenance 1.7 or 2.4 mg
- Frequency
- Once weekly
- Route studied or labeled
- Subcutaneous
2.4 mg is the recommended maintenance amount.
Wegovy HD
Adults needing additional weight reduction under labeled criteria
- Amount
- 7.2 mg
- Frequency
- Once weekly
- Route studied or labeled
- Subcutaneous
Only after tolerating 2.4 mg for at least four weeks.
Wegovy tablets
Adults meeting labeled weight-management or cardiovascular-risk criteria
- Amount
- 1.5 → 4 → 9 mg, each for 30 days; 25 mg maintenance
- Frequency
- Once daily
- Route studied or labeled
- Oral
Fasting product-specific administration; not approved for pediatric or MASH treatment.
Ozempic injection
Adults with type 2 diabetes
- Amount
- 0.25 mg for four weeks, then 0.5 mg; eligible increases to 1 and 2 mg after at least four weeks per step
- Frequency
- Once weekly
- Route studied or labeled
- Subcutaneous
Diabetes product; 0.25 mg is initiation, not glycemic maintenance.
Rybelsus tablets
Adults with type 2 diabetes
- Amount
- 3 mg for 30 days; 7 mg for the next 30 days; then 7 or 14 mg according to glycemic need
- Frequency
- Once daily
- Route studied or labeled
- Oral
Fasting tablet formulation; 3 mg is initiation, not glycemic maintenance.
Ozempic tablets
Adults with type 2 diabetes
- Amount
- 1.5 mg for 30 days; 4 mg for the next 30 days; then 4 or 9 mg according to glycemic need
- Frequency
- Once daily
- Route studied or labeled
- Oral
Distinct from injection; not substitutable mg-for-mg with Rybelsus.
Wegovy injection: MASH
Adults with noncirrhotic MASH and fibrosis stages F2–F3
- Amount
- 2.4 mg maintenance; may reduce to 1.7 mg if not tolerated
- Frequency
- Once weekly
- Route studied or labeled
- Subcutaneous
Accelerated-approval indication; follows injection escalation.
Wegovy injection: cardiovascular risk
Adults with established cardiovascular disease and obesity or overweight
- Amount
- 1.7 or 2.4 mg maintenance
- Frequency
- Once weekly
- Route studied or labeled
- Subcutaneous
Indication-specific amounts after injection escalation.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Elimination half-life
- Approximately one week.
Formulation differences
- Wegovy, Ozempic injection, Ozempic tablets, and Rybelsus have separate labeled regimens.
- The current oral diabetes label assigns 3/7/14 mg to Rybelsus and 1.5/4/9 mg to Ozempic tablets; these formulations are not substitutable mg-for-mg.
Interactions & precautions
- Insulin or insulin secretagogues increase hypoglycemia risk; delayed gastric emptying can affect oral medicines.
- The label does not recommend combining Wegovy with other semaglutide products or GLP-1 receptor agonists.
What is still unresolved
- A plasma half-life does not predict when an individual will notice weight loss.
Side effects & risks
- Common gastrointestinal effects can include nausea, vomiting, diarrhea, constipation, and abdominal discomfort.
- Current labels contain important warnings and contraindications, including a boxed warning about thyroid C-cell tumors observed in rodents.
- Other labeled concerns can include pancreatitis, gallbladder disease, kidney injury related to dehydration, and low blood sugar when combined with certain diabetes medicines.
- Compounded products are not FDA-approved and do not undergo the same premarket review for safety, effectiveness, and quality.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Strong human evidence for approved usesMultiple large randomized trials support approved uses. Evidence for a specific goal must still be matched to the product, population, outcome, and current label.
Studies
Registry record for the SELECT semaglutide cardiovascular outcomes trial.
Peer-reviewed report of a large semaglutide cardiovascular outcomes trial.
What do the human studies show?
Selected research questions, not a complete inventory of indications or trials. Source checking is not independent clinical review. How we read the evidence.
| Study and people | Question and follow-up | Result and limits |
|---|---|---|
| SELECT Age 45+, established cardiovascular disease, BMI ≥27, no diabetes 17,604 participants (actual) Randomized placebo-controlled trial; human | Semaglutide versus Placebo Mean follow-up 39.8 months Primary: First cardiovascular death, nonfatal heart attack or nonfatal stroke Phase: Not listed in this summary | 569/8803 (6.5%) versus 701/8801 (8.0%) had a primary event. 1.5 percentage points fewer events, using rounded published proportions. Hazard ratio 0.80; 95% CI 0.72–0.90. A hazard ratio is not a risk ratio. Cannot tell us: A secondary-prevention population; not a trial in healthy adults or a head-to-head comparison. Safety, uncertainty, and source detailsDiscontinuation due to adverse events: 16.6% versus 8.2%. Limited to the studied population, formulation and follow-up. Funding/conflicts: Funded by Novo Nordisk; individual disclosures not fully extracted. Source checked: 2026-09-18. Independent clinical review: not completed. |
What these results can and cannot tell us
What did SELECT establish about cardiovascular events?
Fewer composite cardiovascular events than placebo in the studied high-risk population.
Limit: Does not establish benefit in every population or rank active medicines.
Check the sources: SELECT: cardiovascular outcomes without diabetes (checked 2026-09-18) · Wegovy prescribing information (DailyMed) (checked 2026-09-18)
Do Wegovy tablets and injection have identical indications?
The label separates formulations, ages and the injection-only MASH indication.
Limit: An ingredient-level approval cannot be assigned to all formulations or indications.
Check the sources: Wegovy prescribing information (DailyMed) (checked 2026-09-18)
What is approved, and for whom?
United States records selected for the questions above; not a complete label or a worldwide approval inventory.
Wegovy: Weight management
Subcutaneous injection · Adults with obesity or overweight plus a weight-related condition; ages 12+ with obesity
approved — Adjunct to reduced-calorie diet and increased physical activity. This is label scope, not a recommendation.
Exact linked source and stated indication only; not an exhaustive regulatory search.
Read the original source · Source checked: 2026-09-18
Wegovy: Weight management
Oral tablet · Adults with obesity or overweight plus a weight-related condition
approved — Do not transfer pediatric injection scope to tablets.
Exact linked source and stated indication only; not an exhaustive regulatory search.
Read the original source · Source checked: 2026-09-18
Wegovy: MASH
Subcutaneous injection · Adults with noncirrhotic MASH and fibrosis consistent with F2–F3
accelerated approval — Based on MASH and fibrosis improvement; continued approval may depend on confirmatory clinical benefit.
Exact linked source and stated indication only; not an exhaustive regulatory search.
Read the original source · Source checked: 2026-09-18
Wegovy: MASH
Oral tablet · MASH population
not in label — The reviewed label assigns this indication to injection, not tablets. Absence from this label is not a global regulatory search.
Exact linked source and stated indication only; not an exhaustive regulatory search.
Read the original source · Source checked: 2026-09-18
Wegovy: Cardiovascular outcomes
Subcutaneous injection · Adults with established cardiovascular disease and overweight or obesity
approved — Risk reduction for cardiovascular death, nonfatal myocardial infarction or nonfatal stroke.
Exact linked source and stated indication only; not an exhaustive regulatory search.
Read the original source · Source checked: 2026-09-18
Compare research questions · Submit a source-based correction
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 4 sourced accounts by reported effect.
Appetite: reported experiences
Fewer cravings without troublesome symptoms
An Ozempic reviewer described six weeks of less interest in food and fewer sugar cravings without noticeable adverse symptoms.
Reported use in this account
- Product
- Ozempic
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Injection; specific route not stated
- Duration
- Six weeks
This selected March 2023 account describes off-label weight-loss use of Ozempic. It does not establish tolerability for everyone or transfer its experience to every semaglutide formulation.
Read the original accountLess intense hunger, with nausea
A person describing their first week with Ozempic reported calmer hunger and some nausea after meals.
Reported use in this account
- Product
- Ozempic
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Injection; specific route not stated
- Duration
- One week after the first injection
Selected public self-report; identity, product contents, other exposures and outcomes were not independently verified. It cannot establish causation or frequency.
Read the first-week reportWeight loss without quieter food thoughts
Another person reported no change in persistent food thoughts after two months, despite nausea that made eating difficult and accompanying weight loss.
Reported use in this account
- Product
- Product labeled semaglutide
- Amount
- 0.5 mg, as reported
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Two months
The product formulation and medical history are unclear. Weight loss alone does not show improved wellbeing; this is one unverified account.
Read the contrasting reportWeight: reported experiences
Weight loss without quieter food thoughts
Another person reported no change in persistent food thoughts after two months, despite nausea that made eating difficult and accompanying weight loss.
Reported use in this account
- Product
- Product labeled semaglutide
- Amount
- 0.5 mg, as reported
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Two months
The product formulation and medical history are unclear. Weight loss alone does not show improved wellbeing; this is one unverified account.
Read the contrasting reportEnergy: reported experiences
Severe stomach symptoms interfered with work
Another Ozempic reviewer described reflux, vomiting, constipation, headache and dizziness after starting, with several days away from work.
Reported use in this account
- Product
- Ozempic
- Amount
- Not specified clearly
- Frequency
- One injection reported
- Route
- Injection; specific route not stated
- Duration
- Symptoms described five days after the first injection
This selected July 2021 review is unverified and does not estimate event frequency or rule out other causes.
Read the original accountDigestion: reported experiences
Severe stomach symptoms interfered with work
Another Ozempic reviewer described reflux, vomiting, constipation, headache and dizziness after starting, with several days away from work.
Reported use in this account
- Product
- Ozempic
- Amount
- Not specified clearly
- Frequency
- One injection reported
- Route
- Injection; specific route not stated
- Duration
- Symptoms described five days after the first injection
This selected July 2021 review is unverified and does not estimate event frequency or rule out other causes.
Read the original accountLess intense hunger, with nausea
A person describing their first week with Ozempic reported calmer hunger and some nausea after meals.
Reported use in this account
- Product
- Ozempic
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Injection; specific route not stated
- Duration
- One week after the first injection
Selected public self-report; identity, product contents, other exposures and outcomes were not independently verified. It cannot establish causation or frequency.
Read the first-week reportWeight loss without quieter food thoughts
Another person reported no change in persistent food thoughts after two months, despite nausea that made eating difficult and accompanying weight loss.
Reported use in this account
- Product
- Product labeled semaglutide
- Amount
- 0.5 mg, as reported
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Two months
The product formulation and medical history are unclear. Weight loss alone does not show improved wellbeing; this is one unverified account.
Read the contrasting reportHeadache: reported experiences
Severe stomach symptoms interfered with work
Another Ozempic reviewer described reflux, vomiting, constipation, headache and dizziness after starting, with several days away from work.
Reported use in this account
- Product
- Ozempic
- Amount
- Not specified clearly
- Frequency
- One injection reported
- Route
- Injection; specific route not stated
- Duration
- Symptoms described five days after the first injection
This selected July 2021 review is unverified and does not estimate event frequency or rule out other causes.
Read the original accountApproval status
Semaglutide approvals are product-specific. Wegovy injection and tablets have distinct population scopes. Wegovy injection also has an accelerated-approval indication for adults with noncirrhotic MASH and F2–F3 fibrosis; that indication is not assigned to tablets in the reviewed label. Other products have their own diabetes, kidney or cardiovascular label scope.
Approved uses
- Improving blood sugar control in specified people with type 2 diabetes
- Chronic weight management in specified people with obesity or overweight
- Reducing specified cardiovascular risks in certain labeled populations
- Wegovy injection: noncirrhotic MASH with F2–F3 fibrosis in adults, under accelerated approval
FDA approved for product-specific uses
Product labels separate diabetes, weight, cardiovascular and other indications. Wegovy injection has an accelerated-approval MASH indication in a defined adult population; the reviewed label does not assign that indication to tablets.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- How every benefit-risk tradeoff changes across individual medical histories
- Whether ongoing trials will support additional labeled indications
- Very long-term outcomes for additional uses and broader populations
- The safety, quality, and equivalence of unapproved products marketed as semaglutide
Summary
Semaglutide has established approved uses. Approval depends on the product, population and indication.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA prescribing information: Wegovy
Official semaglutide prescribing information for a chronic-weight-management product.
- fdaFDA prescribing information: Ozempic
Official semaglutide prescribing information for a type 2 diabetes product.
- fdaFDA: Wegovy cardiovascular risk-reduction approval
FDA announcement describing the approved indication and supporting evidence.
- clinical trialsClinicalTrials.gov: SELECT cardiovascular outcomes trial
Registry record for the SELECT semaglutide cardiovascular outcomes trial.
- pubmedSELECT cardiovascular outcomes trial
Peer-reviewed report of a large semaglutide cardiovascular outcomes trial.
- nihRybelsus and Ozempic tablets current prescribing information
Primary source for the practical reference information.